How much does Daklinza cost?
When Daklinza (daclatasvir) was on the market, the wholesale cost for a 12-week course was roughly $63,000, but patients paid a range of $72,000 to $75,000. Daklinza and the generic daclatasvir was discontinued by Bristol Myers Squibb in 2019 due to business reasons.
Daklinza (daclatasvir) was formerly approved for the treatment of chronic hepatitis C virus (HCV) in adults, in combination with sofosbuvir (brand name: Sovaldi), with or without ribavirin, in genotypes 1 and 3, including hard to treat HCV patients such as those with HIV-1 co-infection, advanced cirrhosis, or post-liver transplant recurrence of HCV.
Daklinza is classified as a HCV NS5A inhibitor.
- Important information about the discontinuation of Daklinza. Bristol Myers Squibb. Accessed March 1, 2021 at https://www.bms.com/patient-and-caregivers/our-medicines/discontinuation-of-daklinza.html